Zobrazeno 1 - 6
of 6
pro vyhledávání: '"F. J. Legat"'
Autor:
I. M. Stender, H. C. Wulf, F. J. Legat, M. De Rie, O. Larkö, A. M. Wennberg, A. M. Solér, P. Wolf, C. Fritsch, R. Kaufmann, Lesley E. Rhodes, T. Warloe, M. Horn, G. A E Wong
Publikováno v:
British journal of dermatology, 149(6), 1242-1249. Wiley-Blackwell
Summary Background Conventional treatment of basal cell carcinoma (BCC) causes morbidity and/or disfigurement in some patients because of the location (e.g. mid-face) and size of the lesion. Objectives Following reports that such difficult-to-treat B
Autor:
P, Wolf, W, Weger, F J, Legat, T, Posch-Fabian, A, Gruber-Wackernagel, M, Inzinger, W, Salmhofer, A, Hofer
Publikováno v:
The British journal of dermatology. 166(1)
Treatment with the interleukin-12/23 antibody ustekinumab produces a satisfactory response [i.e. 75% reduction in Psoriasis Area and Severity Index (PASI) compared with baseline (PASI 75)] in the majority of patients with moderate to severe chronic p
Autor:
M, Inzinger, B, Heschl, W, Weger, A, Hofer, F J, Legat, A, Gruber-Wackernagel, H, Tilz, W, Salmhofer, F, Quehenberger, P, Wolf
Publikováno v:
The British journal of dermatology. 165(3)
Few studies have directly compared the clinical efficacy of psoralen plus ultraviolet A (PUVA) vs. biologics in the treatment of psoriasis.To compare the clinical efficacy of PUVA and biologic therapies for psoriasis under daily life conditions.Data
Autor:
A, Gruber-Wackernagel, I, Bambach, F J, Legat, A, Hofer, S N, Byrne, F, Quehenberger, P, Wolf
Publikováno v:
The British journal of dermatology. 165(1)
Polymorphic light eruption (PLE) is a very frequent photodermatosis whose pathogenesis may involve resistance to ultraviolet (UV)-induced immune suppression. Similar to UV radiation, calcitriol (1,25-dihydroxyvitamin D₃) and its analogues such as c
Publikováno v:
British journal of pharmacology. 121(3)
1. The non-peptide bradykinin (BK) antagonist (E)-3-(6-acetamido-3-pyridyl)-N-[N-[2,4-dichloro-3-[(2-methyl-8-quinolin yl) oxymethyl]phenyl]-N-methylaminocarbonylmethyl]acrylamide (FR173657) was tested in intestinal, uterine, tracheal and vascular in
Publikováno v:
Agents and actions. Supplements. 38
The novel, potent and long-acting bradykinin (BK) antagonists, HOE 140, compound II and compound III, slightly decreased blood pressure, but did not affect heart rate and respiration of rats. The antagonists did not cause bronchoconstriction in guine